Anne-Marie A Wills, Adriana Pérez, Jue Wang, Xiao Su, John Morgan, Suja S Rajan, Maureen A Leehey, Gregory M Pontone, Kelvin L Chou, Chizoba Umeh, Zoltan Mari, James Boyd
IMPORTANCE: Greater body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) is associated with improved survival among persons with Huntington disease or amyotrophic lateral sclerosis. Weight loss is common among persons with Parkinson disease (PD) and is associated with worse quality of life. OBJECTIVE: To explore the association between change in BMI, Unified Parkinson's Disease Rating Scale (UPDRS) motor and total scores, and survival among persons with PD and to test whether there is a positive association between BMI at randomization and survival...
March 2016: JAMA Neurology
O V Tveiten, G O Skeie, K Haugarvoll, B Müller, J P Larsen, O B Tysnes
OBJECTIVES: There are limited data on treatment effect in early and drug-naïve Parkinson's disease (PD) outside of clinical trials. We sought to review the treatment effects on motor symptoms in early, unselected PD patients. METHODS: We included 183 drug-naïve patients from a longitudinal cohort (The Norwegian ParkWest study). At the time of diagnosis, motor symptoms were assessed and rated. Treatment was unrestricted, aimed at treating each patient optimally...
August 2013: Acta Neurologica Scandinavica
Huijing Liu, Wen Su, Shuhua Li, Wei Du, Xinxin Ma, Ying Jin, Kai Li, Haibo Chen
OBJECTIVES: Previous studies have shown that Helicobacter pylori infection might make clinical status worse in patients with Parkinson's disease and Helicobacter pylori eradication might improve clinical status by modifying the pharmacokinetics of L-dopa. Here, we investigate whether Helicobacter pylori eradication could benefit idiopathic parkinsonism and Helicobacter pylori infection will effect which aspect of motor symptom significantly. PATIENTS AND METHODS: A cohort study involving idiopathic Parkinson's disease patients, screened for Helicobacter status by 13 C urea breath test...
September 2017: Clinical Neurology and Neurosurgery
Matthew D Johnson, Jianyu Zhang, Debabrata Ghosh, Cameron C McIntyre, Jerrold L Vitek
Clinical evidence has suggested that subtle changes in deep brain stimulation (DBS) settings can have differential effects on bradykinesia and rigidity in patients with Parkinson's disease. In this study, we first investigated the degree of improvement in bradykinesia and rigidity during targeted globus pallidus DBS in three 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rhesus macaques. Behavioral outcomes of DBS were then coupled with detailed, subject-specific computational models of neurons in the globus pallidus internus (GPi), globus pallidus externus (GPe), and internal capsule (IC) to determine which neuronal pathways when modulated with high-frequency electrical stimulation best correlate with improvement in motor symptoms...
July 2012: Journal of Neurophysiology
Antonella Macerollo, Jui-Cheng Chen, Prasad Korlipara, Thomas Foltynie, John Rothwell, Mark John Edwards, James Morvan Kilner
BACKGROUND: The primary motor sign of Parkinson's disease is bradykinesia. It has been surprisingly difficult to provide a clear neurobiological mechanism for this fundamental movement deficit in Parkinson's disease. It has been proposed that in healthy individuals the gating of sensory afferents prior to and during movement is an essential step in initiating movement. This down-weighting has been proposed to account for the attenuation of the somatosensory evoked potential following median nerve stimulation at the onset of and during hand movements...
January 2016: Movement Disorders: Official Journal of the Movement Disorder Society
Julia C Lemos, Danielle M Friend, Alanna R Kaplan, Jung Hoon Shin, Marcelo Rubinstein, Alexxai V Kravitz, Veronica A Alvarez
Bradykinesia is a prominent phenotype of Parkinson's disease, depression, and other neurological conditions. Disruption of dopamine (DA) transmission plays an important role, but progress in understanding the exact mechanisms driving slowness of movement has been impeded due to the heterogeneity of DA receptor distribution on multiple cell types within the striatum. Here we show that selective deletion of DA D2 receptors (D2Rs) from indirect-pathway medium spiny neurons (iMSNs) is sufficient to impair locomotor activity, phenocopying DA depletion models of Parkinson's disease, despite this mouse model having intact DA transmission...
May 18, 2016: Neuron
Markus Mandler, Elvira Valera, Edward Rockenstein, Harald Weninger, Christina Patrick, Anthony Adame, Radmila Santic, Stefanie Meindl, Benjamin Vigl, Oskar Smrzka, Achim Schneeberger, Frank Mattner, Eliezer Masliah
Immunotherapeutic approaches are currently in the spotlight for their potential as disease-modifying treatments for neurodegenerative disorders. The discovery that α-synuclein (α-syn) can transmit from cell to cell in a prion-like fashion suggests that immunization might be a viable option for the treatment of synucleinopathies. This possibility has been bolstered by the development of next-generation active vaccination technology with short peptides-AFFITOPEs(®) (AFF)- that do not elicit an α-syn-specific T cell response...
2014: Acta Neuropathologica
Karl Kieburtz, Barbara C Tilley, Jordan J Elm, Debra Babcock, Robert Hauser, G Webster Ross, Alicia H Augustine, Erika U Augustine, Michael J Aminoff, Ivan G Bodis-Wollner, James Boyd, Franca Cambi, Kelvin Chou, Chadwick W Christine, Michelle Cines, Nabila Dahodwala, Lorelei Derwent, Richard B Dewey, Katherine Hawthorne, David J Houghton, Cornelia Kamp, Maureen Leehey, Mark F Lew, Grace S Lin Liang, Sheng T Luo, Zoltan Mari, John C Morgan, Sotirios Parashos, Adriana Pérez, Helen Petrovitch, Suja Rajan, Sue Reichwein, Jessie Tatsuno Roth, Jay S Schneider, Kathleen M Shannon, David K Simon, Tanya Simuni, Carlos Singer, Lewis Sudarsky, Caroline M Tanner, Chizoba C Umeh, Karen Williams, Anne-Marie Wills
IMPORTANCE: There are no treatments available to slow or prevent the progression of Parkinson disease, despite its global prevalence and significant health care burden. The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson Disease program was established to promote discovery of potential therapies. OBJECTIVE: To determine whether creatine monohydrate was more effective than placebo in slowing long-term clinical decline in participants with Parkinson disease...
February 10, 2015: JAMA
Dan Lindholm, Johanna Mäkelä, Valentina Di Liberto, Giuseppa Mudò, Natale Belluardo, Ove Eriksson, Mart Saarma
Parkinson's disease (PD is a progressive neurological disorder characterized by the degeneration and death of midbrain dopamine and non-dopamine neurons in the brain leading to motor dysfunctions and other symptoms, which seriously influence the quality of life of PD patients. The drug L-dopa can alleviate the motor symptoms in PD, but so far there are no rational therapies targeting the underlying neurodegenerative processes. Despite intensive research, the molecular mechanisms causing neuronal loss are not fully understood which has hampered the development of new drugs and disease-modifying therapies...
April 2016: Cellular and Molecular Life Sciences: CMLS
Kevin M Biglan, David Oakes, Anthony E Lang, Robert A Hauser, Karen Hodgeman, Brittany Greco, Jillian Lowell, Rebecca Rockhill, Ira Shoulson, Charles Venuto, Diony Young, Tanya Simuni
OBJECTIVE: To describe the rationale for a novel study design and baseline characteristics of a disease-modifying trial of isradipine 10 mg daily in early Parkinson disease (PD). METHODS: STEADY-PDIII is a 36-month, Phase 3, parallel group, placebo-controlled study of the efficacy of isradipine 10 mg daily in 336 participants with early PD as measured by the change in the Unified Parkinson Disease Rating Scale (UPDRS) Part I-III score in the practically defined ON state...
June 2017: Annals of Clinical and Translational Neurology
Michael A Schwarzschild, Alberto Ascherio, M Flint Beal, Merit E Cudkowicz, Gary C Curhan, Joshua M Hare, D Craig Hooper, Karl D Kieburtz, Eric A Macklin, David Oakes, Alice Rudolph, Ira Shoulson, Marsha K Tennis, Alberto J Espay, Maureen Gartner, Albert Hung, Grace Bwala, Richard Lenehan, Elmyra Encarnacion, Melissa Ainslie, Richard Castillo, Daniel Togasaki, Gina Barles, Joseph H Friedman, Lisa Niles, Julie H Carter, Megan Murray, Christopher G Goetz, Jeana Jaglin, Anwar Ahmed, David S Russell, Candace Cotto, John L Goudreau, Doozie Russell, Sotirios Andreas Parashos, Patricia Ede, Marie H Saint-Hilaire, Cathi-Ann Thomas, Raymond James, Mark A Stacy, Julia Johnson, Lisa Gauger, J Antonelle de Marcaida, Sheila Thurlow, Stuart H Isaacson, Lisbeth Carvajal, Jayaraman Rao, Maureen Cook, Charlise Hope-Porche, Lauren McClurg, Daniela L Grasso, Robert Logan, Constance Orme, Tori Ross, Alicia F D Brocht, Radu Constantinescu, Saloni Sharma, Charles Venuto, Joseph Weber, Ken Eaton
IMPORTANCE: Convergent biological, epidemiological, and clinical data identified urate elevation as a candidate strategy for slowing disability progression in Parkinson disease (PD). OBJECTIVE: To determine the safety, tolerability, and urate-elevating capability of the urate precursor inosine in early PD and to assess its suitability and potential design features for a disease-modification trial. DESIGN, SETTING, AND PARTICIPANTS: The Safety of Urate Elevation in PD (SURE-PD) study, a randomized, double-blind, placebo-controlled, dose-ranging trial of inosine, enrolled participants from 2009 to 2011 and followed them for up to 25 months at outpatient visits to 17 credentialed clinical study sites of the Parkinson Study Group across the United States...
February 2014: JAMA Neurology
(no author information available yet)
BACKGROUND: Treatment with rasagiline mesylate, an irreversible monoamine oxidase type B inhibitor, improves symptoms of early Parkinson disease (PD). Preclinical studies suggest that this compound may also modify the progression of PD. OBJECTIVE: To compare the effects of early and later initiation of rasagiline on progression of disability in patients with PD. DESIGN: Double-blind, parallel-group, randomized, delayed-start clinical trial...
April 2004: Archives of Neurology
(no author information available yet)
Isradipine, a dihydropyridine calcium channel antagonist, has been shown to be neuroprotective in animal models of Parkinson's disease (PD). To establish a dosage of isradipine controlled-release (CR) that is tolerable and demonstrates preliminary efficacy for use in a future pivotal efficacy trial a Phase 2, randomized, double-blind, parallel group trial (Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease [STEADY-PD]) was undertaken in subjects with early PD not requiring dopaminergic therapy (dopamine agonists or levodopa) randomized 1:1:1:1 to 5, 10, or 20 mg of isradipine CR or matching placebo daily...
November 2013: Movement Disorders: Official Journal of the Movement Disorder Society
C Rodriguez-Blazquez, M J Forjaz, B Frades-Payo, J de Pedro-Cuesta, P Martinez-Martin
BACKGROUND AND PURPOSE: Autonomic dysfunction is common in Parkinson's disease (PD) and causes a great impact in health-related quality of life (HRQL) and functional status of patients. This study is the first independent validation of the Scales for Outcomes in PD-Autonomic (SCOPA-AUT). METHODS: In an observational, cross-sectional study (ELEP Study), 387 PD patients were assessed using, in addition to the SCOPA-AUT, the Hoehn and Yahr staging, SCOPA-Motor, SCOPA-Cognition, Cumulative Illness Rating Scale-Geriatrics, modified Parkinson Psychosis Rating Scale, Clinical Impression of Severity Index for PD, Hospital Anxiety and Depression Scale, SCOPA-Sleep, SCOPA-Psychosocial, pain and fatigue visual analogue scales, and EQ-5D...
February 2010: European Journal of Neurology
Kyle B Fraser, Ashlee B Rawlins, Rachel G Clark, Roy N Alcalay, David G Standaert, Nianjun Liu, Andrew B West
BACKGROUND: Mutations in Leucine-rich repeat kinase 2 (LRRK2) enhance levels of the autophosphorylated LRRK2 protein and are the most common known cause of inherited Parkinson's disease (PD). LRRK2 has been further implicated in susceptibility to idiopathic PD in genetic association studies. OBJECTIVE: The objective of this study was to compare autophosphorylated Ser(P)-1292 LRRK2 levels from biobanked urine samples with clinical data in PD patients and controls...
October 2016: Movement Disorders: Official Journal of the Movement Disorder Society
Valerie Voon, T Celeste Napier, Michael J Frank, Veronique Sgambato-Faure, Anthony A Grace, Maria Rodriguez-Oroz, Jose Obeso, Erwan Bezard, Pierre-Olivier Fernagut
Dopaminergic medications used in the treatment of patients with Parkinson's disease are associated with motor and non-motor behavioural side-effects, such as dyskinesias and impulse control disorders also known as behavioural addictions. Levodopa-induced dyskinesias occur in up to 80% of patients with Parkinson's after a few years of chronic treatment. Impulse control disorders, including gambling disorder, binge eating disorder, compulsive sexual behaviour, and compulsive shopping occur in about 17% of patients with Parkinson's disease on dopamine agonists...
March 2017: Lancet Neurology
Robert G Holloway, Ira Shoulson, Stanley Fahn, Karl Kieburtz, Anthony Lang, Kenneth Marek, Michael McDermott, John Seibyl, William Weiner, Bruno Musch, Cornelia Kamp, Mickie Welsh, Aileen Shinaman, Rajesh Pahwa, Lynn Barclay, Jean Hubble, Peter LeWitt, Janis Miyasaki, Oksana Suchowersky, Mark Stacy, David S Russell, Blair Ford, John Hammerstad, David Riley, David Standaert, Frederick Wooten, Stewart Factor, Joseph Jankovic, Farah Atassi, Roger Kurlan, Michel Panisset, Ali Rajput, Robert Rodnitzky, Cliff Shults, Giselle Petsinger, Cheryl Waters, Ronald Pfeiffer, Kevin Biglan, Leona Borchert, Amy Montgomery, Laura Sutherland, Carolyn Weeks, Maryan DeAngelis, Elspeth Sime, Susan Wood, Carol Pantella, Mary Harrigan, Barbara Fussell, Sandra Dillon, Barbara Alexander-Brown, Pamela Rainey, Marsha Tennis, Elke Rost-Ruffner, Diane Brown, Sharon Evans, Debra Berry, Jean Hall, Theresa Shirley, Judith Dobson, Deborah Fontaine, Brenda Pfeiffer, Alicia Brocht, Susan Bennett, Susan Daigneault, Karen Hodgeman, Carolynn O'Connell, Tori Ross, Karen Richard, Arthur Watts
BACKGROUND: The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear. OBJECTIVE: To compare initial treatment with pramipexole vs levodopa in early Parkinson disease, followed by levodopa supplementation, with respect to the development of dopaminergic motor complications, other adverse events, and functional and quality-of-life outcomes. DESIGN: Multicenter, parallel-group, double-blind, randomized controlled trial...
July 2004: Archives of Neurology
Claudia Trenkwalder, K Ray Chaudhuri, Pedro J García Ruiz, Peter LeWitt, Regina Katzenschlager, Friederike Sixel-Döring, Tove Henriksen, Ángel Sesar, Werner Poewe, Mary Baker, Andres Ceballos-Baumann, Günther Deuschl, Sophie Drapier, Georg Ebersbach, Andrew Evans, Hubert Fernandez, Stuart Isaacson, Teus van Laar, Andrew Lees, Simon Lewis, Juan Carlos Martínez Castrillo, Pablo Martinez-Martin, Per Odin, John O'Sullivan, Georgios Tagaris, Karoline Wenzel
Extensive published evidence supports the use of subcutaneously-administered apomorphine as an effective therapy for Parkinson's disease (PD) but to date no consensus recommendations have been available to guide healthcare professionals in the optimal application of apomorphine therapy in clinical practice. This document outlines best-practice recommendations for selecting appropriate candidates for apomorphine intermittent injection (the pen-injection formulation) or apomorphine continuous infusion (the pump formulation), for initiating patients onto therapy and for managing their ongoing treatment...
September 2015: Parkinsonism & related Disorders
(no author information available yet)
BACKGROUND: Rasagiline (n-propargyl-1[R]-aminoindan) mesylate is a novel irreversible selective monoamine oxidase type B inhibitor, previously demonstrated to improve symptoms in early Parkinson disease (PD). OBJECTIVE: To determine the safety, tolerability, and efficacy of rasagiline in levodopa-treated patients with PD and motor fluctuations. DESIGN: Multicenter, randomized, placebo-controlled, double-blind, parallel-group study. PATIENTS: Parkinson disease patients (N = 472) with at least 21/2 hours of daily "off" (poor motor function) time, despite optimized treatment with other anti-PD medications...
February 2005: Archives of Neurology
(no author information available yet)
OBJECTIVE: To compare the long-term outcomes of subjects initially treated with pramipexole dihydrochloride with those of subjects initially treated with levodopa in the Comparison of the Agonist Pramipexole With Levodopa on Motor Complications of Parkinson's Disease (CALM-PD) trial. DESIGN: Up to 2 years of open extended follow-up of the CALM-PD subjects. SETTING: Academic movement disorders clinics at 22 sites in the United States and Canada...
May 2009: Archives of Neurology
2017-07-11 18:46:41
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"